April 3, 2026

FTC Formalizes Aggressive Health Care Enforcement With New Task Force

Jesse Coleman, Yumna Khan Seyfarth Shaw LLP + Follow Contact LinkedIn Facebook X Send Embed The Federal Trade Commission (“FTC”) has put health care front and center in its enforcement agenda. On March 20, 2026, FTC Chairman Andrew Ferguson announced the creation of a “Healthcare Task Force” to align the agency’s competition and consumer‑protection work. The move reflects a core FTC concern: consolidation, exclusionary conduct, and deceptive practices are raising prices, weakening quality, and restricting access to care—especially for rural patients, seniors, and veterans.

Chairman Ferguson’s memorandum announcing the Task Force frames health care as well-suited for coordinated enforcement. The industry is vast, complex, and consequential. To meet that reality, the Task Force draws staff from the Bureaus of Competition, Consumer Protection, and Economics, as well as the Office of Policy Planning, Office of Technology, and Office of the General Counsel. Its charge extends beyond internal coordination to active collaboration with sister agencies, including the Department of Health and Human Services and the Department of Justice. Rather than a short‑term initiative, the Task Force reflects an effort to institutionalize health care enforcement across the agency and move toward more proactive, cross‑bureau investigations.

The Task Force also formalizes an enforcement posture the FTC has already been executing. In January 2026, the FTC secured a preliminary injunction blocking a proposed $945 million acquisition between two prominent medical device suppliers—preserving head‑to‑head competition and expanding treatment options for patients suffering from potentially fatal heart conditions. That same month, the FTC also challenged a merger between two national providers of residential services for individuals with intellectual and developmental disabilities (“IDD services”), citing risks to competition among community‑based care providers. The agency’s action required significant divestitures to maintain competitive choice in local IDD services markets.

In March 2026, the FTC reached a similar conclusion in opposing the proposed merger between two of the most significant players in the market for laser systems used in cataract surgery. There, the agency concluded that the transaction would have ended vigorous price competition and dampened innovation. Together, these matters send a consistent message: loss of innovation and future rivalry can justify intervention, even absent immediate price effects.

At the same time, the FTC has paired competition enforcement with aggressive consumer‑protection actions in health care adjacent markets. In recent years, the agency has obtained substantial monetary relief for alleged deceptive marketing of health insurance products, telehealth services, and substance‑abuse treatment referrals. Most notably, in February 2026, the FTC secured a landmark settlement with one of the nation’s largest pharmacy benefit managers  and its affiliated entities, alleging rebate and contracting practices that inflated insulin prices and disadvantaged patients and independent pharmacies. The settlement imposed material changes to pricing and transparency, with the FTC projecting billions of dollars in patient savings.

Taken together, these actions explain why the FTC chose to institutionalize its health care focus through a dedicated Task Force. For providers, manufacturers, payors, digital health companies, and investors, the message is unmistakable. The FTC is scrutinizing not only consolidation, but also contracts, regulatory positioning, and competition for innovation itself. As the Task Force gets to work, health care businesses should expect a more unified—and more assertive—enforcement posture.

Key Takeaways

• The FTC is integrating merger enforcement, conduct investigations, and consumer‑protection actions into a single health care framework.

• Health care companies should anticipate earlier intervention and broader remedies driven by coordinated enforcement.
  Send Print Report

  Latest Posts

• FTC Formalizes Aggressive Health Care Enforcement With New Task Force

• The Week in Weed: April 2026

• Navigating DOJ’s New Voluntary Self-Disclosure Framework in Government Contracting

• Proposed Department of Labor Rule Enumerates ERISA Fiduciary Duties for Selecting Alternative Investments in 401(k) Plans

• Workforce Reductions in Washington: Lawmakers Refine Mini‑WARN Requirements and Broaden Unemployment Benefits for Layoff Volunteers
  See more »

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
Attorney Advertising.

©
Seyfarth Shaw LLP

Written by:

Seyfarth Shaw LLP Contact + Follow Jesse Coleman + Follow Yumna Khan + Follow more less

PUBLISH YOUR CONTENT ON JD SUPRA

• ✔ Increased readership
• ✔ Actionable analytics
• ✔ Ongoing writing guidance Join more than 70,000 authors publishing their insights on JD Supra

Start Publishing »

Published In:

Antitrust Investigations + Follow Competition + Follow Consumer Protection Laws + Follow Department of Health and Human Services (HHS) + Follow Enforcement Actions + Follow Federal Agency Taskforce + Follow Federal Trade Commission (FTC) + Follow Healthcare + Follow Medical Devices + Follow Pharmacy Benefit Manager (PBM) + Follow Rural Health Care Program + Follow Veterans + Follow Antitrust & Trade Regulation + Follow General Business + Follow Consumer Protection + Follow Health + Follow Mergers & Acquisitions + Follow more less

Seyfarth Shaw LLP on:

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Sign Up Log in ** By using the service, you signify your acceptance of JD Supra's Privacy Policy.* - hide - hide